This Medication Guide section is provided for general educational purposes only
3 The UK National Institute for Health and Care Excellence (NICE) states that a cut-off of 200 ng/l identifies 97% of people with B12 deficiency, and a level below 100 ng/l is usually accompanied by metabolic or clinical evidence of B12 deficiency
If you think youre deficient, talk with a healthcare professional to figure out the best option for you
Product Information Product Name: BPC-157 Form: Lyophilized synthetic peptide powder Peptide Length: 15 amino acids Purity: At or above 98% (see batch-specific Certificate of Analysis) Testing: Batch-specific third-party HPLC, Mass Spectrometry (MS), and Endotoxin (LAL) testing available Intended Use: Research use only Storage: Store according to recommended laboratory handling procedures
Archived from the original on August 21, 2013
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
